Tomas Kiselak
Sits on 8 boards. Overboarded · 8 public boards Last updated September 27, 2026
Time on boards
- Boards served
- 8
- Current seats
- 8
- Board service
- 17 years
- Director since
- 2023
17 years of board service in total across 8 boards, counting each seat separately. Longest: Viridian Therapeutics Inc., 3 years.
Viridian Therapeutics Inc.
Director
Spyre Therapeutics Inc.
Director
Dianthus Therapeutics Inc.
Director
Oruka Therapeutics Inc.
Director
Zenas BioPharma Inc.
Director
Jade Biosciences Inc.
Director
Crescent Biopharma Inc.
Director
Korsana Biosciences Inc.
Director
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 31, 2026 | Zenas BioPharma Inc. | Open-market purchase | +150,000 | $20.00 | $3,000,000 |
| Sep 17, 2025 | Oruka Therapeutics Inc. | Grant or award | +333,340 | $15.00 | $5,000,100 |
| Nov 19, 2024 | Oruka Therapeutics Inc. | Option exercise | +160,000 | — | — |
| Sep 27, 2024 | Dianthus Therapeutics Inc. | Other | −62,146 | — | — |
| Sep 11, 2024 | Oruka Therapeutics Inc. | Grant or award | +275,000 | $23.00 | $6,325,000 |
| Apr 1, 2024 | Dianthus Therapeutics Inc. | Other | −58,857 | — | — |
| Apr 1, 2024 | Dianthus Therapeutics Inc. | Other | +58,857 | — | — |
| Sep 26, 2023 | Dianthus Therapeutics Inc. | Open-market purchase | +30,000 | $13.15 | $394,500 |
| Sep 19, 2023 | Dianthus Therapeutics Inc. | Open-market purchase | +30,000 | $13.20 | $396,000 |
| Sep 13, 2023 | Dianthus Therapeutics Inc. | Open-market purchase | +9,367 | $11.76 | $110,156 |
| Sep 12, 2023 | Dianthus Therapeutics Inc. | Open-market purchase | +14,887 | $10.85 | $161,524 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.